还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
  N9 m: c: j- q: E  C. ]3 o
1 }) ~+ \& r0 Y6 ?
Sub-category:
+ @4 o% D: _% s( {( P7 sMolecular Targets
3 D0 o/ K0 ~$ y9 F
8 E* X! V$ U2 U
% P7 [4 d* C, E6 d; d" hCategory:
Tumor Biology
, K: Q' f; E/ x
1 y( E+ G; a6 T8 w# M( o) `
* `4 ~- o; ]6 K  L6 H& J: tMeeting:
# i, o" O& `' n. r0 w+ o$ V3 t2011 ASCO Annual Meeting
) B3 x- Y% [5 `
9 v+ ~! d# W0 `. A
Session Type and Session Title:
6 t) C$ {  ]% W- W, h/ |Poster Discussion Session, Tumor Biology


9 R7 @. h! D( K' R9 |) S2 iAbstract No:
10517
6 [9 X; |  Q) b. k* e

Citation:
7 u0 [5 P3 W1 T* h& e1 JJ Clin Oncol 29: 2011 (suppl; abstr 10517)
2 z7 f  Z2 [4 S

  a( N) m7 m' D# e' l+ n7 g$ DAuthor(s):
! ~$ D6 s, `) }& f9 {$ m9 DJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
4 y; F+ Q5 L7 p2 z  }
/ I# I6 z8 V6 u3 L

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

- d9 V( w% t5 [; ]0 a' X0 ^4 wAbstract Disclosures

Abstract:
" A4 G8 r" [* P4 d
4 m" }9 q6 L! m- b
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
( ~/ g3 L( O: I1 }8 A) e) u$ M
0 x1 X$ ~* k' O3 F! e

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

5 b* O% e+ M. c                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊